Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Tapentadol Stories

2014-04-03 08:28:55

Product has fast track designation by FDA RALEIGH, N.C., April 3, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today the enrollment of the first patient in the RHAPSODY Study, a Phase 3 clinical trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy. The Phase 3 trial is a multicenter, randomized, double blind, placebo controlled study to determine the efficacy and safety of Clonidine Topical Gel in the treatment...

2014-02-11 20:21:26

DUBLIN, February 11, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/tgtpbg/drug_solubility) has announced the addition of the "Concise Analysis of Drug Solubility Technology: Spray Drying, Extrusion, and SCF" [http://www.researchandmarkets.com/research/tgtpbg/drug_solubility ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) As drug suppliers re-examine their business models to adjust...

2014-02-05 04:20:49

MELBOURNE, Australia, February 5, 2014 /PRNewswire/ -- - Phase 2 trial met its primary endpoint, reduced pain in postherpetic neuralgia (PHN) versus placebo - Significant patient response to EMA401 treatment and drop in pain intensity compared with placebo, meeting a key secondary endpoint - First published demonstration of the therapeutic potential of angiotensin II type 2 (AT2)receptor antagonists - EMA401...

2014-01-16 16:23:41

DUBLIN, January 16, 2014 /PRNewswire/ -- Dublin - Research and Markets ( http://www.researchandmarkets.com/research/sqmftt/pain_therapeutics) has announced the addition of a new report "Pain Therapeutics - Drugs, Markets and Companies" [http://www.researchandmarkets.com/research/sqmftt/pain_therapeutics ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) This report describes the latest concepts of pathomechanisms of pain as a basis...

2013-12-13 08:24:43

- 30 mcg sufentanil NanoTab treatment group experienced rapid onset of action with statistically significant pain relief and reduced pain intensity at 30 minutes - REDWOOD CITY, Calif., Dec. 13, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today presented additional detail from the Phase 2 dose-finding study...

2013-12-03 08:31:24

THE WOODLANDS, Texas, Dec. 3, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome (IBS-d). LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome. The primary endpoint of this...

2013-12-02 08:30:12

Phase 3 to begin first quarter 2014; Fast track designation confirmed for NDA program RALEIGH, N.C., Dec. 2, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that it engaged in a positive meeting with the U.S. Food and Drug Administration (FDA) regarding the clinical development program for Clonidine Topical Gel that will allow the program to proceed to Phase 3 clinical studies in the first quarter of 2014. (Logo:...

2013-11-26 08:27:16

STAMFORD, Conn., Nov. 26, 2013 /PRNewswire/ -- Purdue Pharma L.P. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for Targiniq(TM) ER (oxycodone HCl/naloxone HCl controlled-release) Tablets CII, for the management of chronic pain. "This milestone brings us closer to offering an important treatment option for the management of chronic pain," said Gary L. Stiles, MD, Purdue Pharma's Senior Vice President of...

2013-11-19 08:27:33

SAN FRANCISCO, Nov. 19, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca announced that the United States Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for naloxegol, an investigational peripherally-acting mu-opioid receptor antagonist (PAMORA), which has been studied in opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, the most common side effect( )caused by chronic...

2013-11-07 23:01:54

Reportbuyer.com just published a new market research report: Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline London (PRWEB) November 07, 2013 Summary GBI Research’s report “Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline“ provides insights and analysis into the market....